UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 10, 2012
SeraCare Life Sciences, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | | 001-34105 | | 33-0056054 |
(State or other jurisdiction of incorporation) | | (Commission file number) | | (IRS Employer Identification No.) |
37 Birch Street, Milford, Massachusetts 01757
(Address of principal executive offices)
Registrant’s telephone number, including area code: (508) 244-6400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On February 10, 2012, we issued a press release announcing our financial results for the quarter ended December 31, 2011. A copy of the press release is attached hereto as exhibit 99.1 and incorporated by reference herein.
The information in this Item 2.02 and the press release attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
| Exhibit No. | Description |
| | |
| 99.1 | Press Release issued by SeraCare Life Sciences, Inc. dated February 10, 2012. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | SERACARE LIFE SCIENCES, INC. |
| | | | |
| | By: | /s/ Gregory A. Gould |
| | | Name: | Gregory A. Gould |
| | | Title: | Interim President and Chief Executive |
| | | | Officer, Chief Financial Officer, |
| | | | Secretary and Treasurer |
| | | | |
| Dated: February 10, 2012 | | | |
EXHIBIT INDEX
| Exhibit No. | Description |
| | |
| 99.1 | Press Release issued by SeraCare Life Sciences, Inc. dated February 10, 2012. |
